ASCO, page-21

2011 phase II

RESULTS:

There were no treatment-related deaths. There was only one treatment-related hospitalization and 2 grade 4 toxicities. In the cisplatin arm, there were 3 partial responses, 9 patients (56%) achieved stable disease, 4 (25%) progressed, and the overall best response rate was 19%. In the paclitaxel arm, there was one complete response and 2 partial responses, 8 patients (53%) achieved stable disease, 4 patients (27%) progressed, and the overall best response rate was 20%.

DISCUSSION:
The combination of IV phenoxodiol with cisplatin or paclitaxel was well tolerated in this study. Cisplatin-phenoxodiol was particularly active and warrants further study in patients with platinum-resistant ovarian cancer.

https://www.ncbi.nlm.nih.gov/pubmed/21412168?dopt=Abstract

(average time frame six months)
https://clinicaltrials.gov/ct2/show/study/NCT00091377?term=novogen&rank=1

Good results back in 2011 as well.